Oncology Xagena
In the phase 3 CheckMate 227 Part 1 ( minimum follow-up, 29.3 months ), first line 1L Nivolumab ( Opdivo ) + Ipilimumab ( Yervoy ) has significantly improved overall survival ( OS ) versus chemotherap ...
This is the first randomized trial testing the addition of an oncolytic virus to an immune checkpoint inhibitor for advanced melanoma. At the 3-year follow-up, the combination ( combo ) of Talimog ...
Selpercatinib ( Retevmo ) is a highly selective and potent small molecule RET kinase inhibitor. Researchers have reported an update on the efficacy and safety of Selpercatinib in RET-fusion+ non-smal ...
Previous treatment with immune checkpoint inhibitor ( ICI ) is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for metastatic urothelial carcino ...
Treatment of patients with BRAF V600–mutant melanoma includes BRAF/MEK-inhibitor combinations based on demonstrated benefits on progression-free survival ( PFS ) and overall survival ( OS ). To bett ...
First-line immunotherapy with / without chemotherapy is standard of care for patients with advanced non-small-cell lung cancer ( NSCLC ); however, there is a need for effective treatment options after ...
Approximately, 95% of patients who have an initial response to ALK tyrosine kinase inhibitors ( ALK-TKIs ) exhibit an incomplete response resulting in residual disease that enables the emergence of ac ...
Pembrolizumab ( Keytruda ) monotherapy has shown promising antitumor activity and manageable safety in patients with metastatic triple-negative breast cancer ( TNBC ) in KEYNOTE-012, -086 and -119. ...
Tivozanib ( Fotivda ) is a potent and highly selective VEGFR inhibitor. TIVO-3 is a phase 3 study designed to compare the efficacy and safety of Tivozanib with those of Sorafenib ( Nexavar ) as 3rd an ...
Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response represents a major challenge. Tomivosertib, a potent and highly selec ...
Lorlatinib ( Lorviqua ) is a 3rd-generation ALK tyrosine kinase inhibitor ( TKI ) developed to penetrate the central nervous system ( CNS ) and overcome resistance to 2nd-generation ( 2nd-gen ) ALK TK ...
Final, mature progression-free survival ( PFS ) from the global phase III ALEX study of Alectinib ( Alecensa ) vs Crizotinib ( Xalkori ) in untreated, advanced / metastatic anaplastic lymphoma kinase- ...
In Part 1 of the phase II CheckMate 568 study, Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) was active and tolerable in patients with advanced non-small cell lung cancer ( NSCLC ). The addition of ...
In the phase 2 CheckMate 142 trial, Nivolumab ( Opdivo ) plus low-dose Ipilimumab ( Yervoy ) has provided robust and durable clinical benefit and was well tolerated as first-line therapy for microsate ...
The randomized, open-label, phase 3 KEYNOTE-426 study has demonstrated that Pembrolizumab ( Keytruda ) + Axitinib ( Inlyta ) significantly improved overall survival ( OS ), progression-free survival ( ...
